Patents - Global Data - Dimensions
Grant
Daptomycin formulation
Applicants
- Xellia (Denmark)
[NORA names: Xellia; Private Research]
Abstract
The present disclosure relates to a solid formulation of daptomycin comprising at least one branched aliphatic amino acid. Solid daptomycin formulation of the present disclosure shows improved reconstituted time. The disclosure further relates to a method of preparation of the solid daptomycin formulation according to this disclosure.
Patent Family Records (10)
Daptomycin formulation
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMIC BARBARA
2024, AU-2021227095-B2
DAPTOMYCIN FORMULATION
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMIC BARBARA
2023, US-20230068866-A1
Daptomycin preparation
Xellia (Denmark), Xellia Pharmaceuticals ApS フミッチ、バルバラ
2023, JP-2023516957-A
DAPTOMYCIN FORMULATION
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMIC BARBARA
2023, EP-4110303-A1
DAPTOMYCIN FORMULATION.
XELLIA PHARMACEUTICALS APS, Xellia (Denmark) FUMIC BARBARA
2022, MX-2022010378-A
Daptomycin formulations
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMICI BARBARA
2022, CN-115038431-A
DAPTOMICIN FORMULATION.
XELLIA PHARMACEUTICALS APS, Xellia (Denmark) BARBARA FUMIC
2022, BR-112022015571-A2
Daptomycin formulation
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMIC BARBARA
2022, AU-2021227095-A1
DAPTOMYCIN FORMULATION
XELLIA PHARMACEUTICALS APS, Xellia (Denmark) FUMIC BARBARA
2021, WO-2021170807-A1
DAPTOMYCIN FORMULATION WITH BRANCHED AIPHATIC AMINO ACID
Individual FUMIC BARBARA
2021, CA-3168727-A1